Question 1

Am I eligible for this trial based on my current treatment and health status?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Question 2

How does guselkumab compare to my current treatment in terms of effectiveness and side effects?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential risks and benefits of switching to guselkumab?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Question 4

How will my health be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects while participating in the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any travel or logistical considerations I should be aware of for participating in this study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD) clinical trial (NCT07245394). Contact the study team or your healthcare provider for specific answers.

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

What this study is about

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

What this study is about